METHOD, SYSTEM, COMPOSITION AND KIT FOR DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON HUMAN BRAIN HIPPOCAMPUS SPATIAL TRANSCRIPTOMICS
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Zhang, Jing
Wang, Pan
Guo, Zhen
Xu, Zhi
Han, Lei
Pan, Danhua
Abrégé
A method, system, composition and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on human brain hippocampus spatial transcriptomics. The present invention achieves rapid and efficient early diagnosis and differential diagnosis of AD cognitive disorder by means of one or more of CCK, Neurogranin and PMP2 carried in plasma extracellular vesicles (EVs), thereby achieving high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, having the advantages of rapidness and low cost, and providing a new technical means and method for clinical application of AD cognitive disorder and large-scale screening-related accurate diagnosis work.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
2.
ANTI-CORONAVIRUS EFFECT AND APPLICATION OF P14K INHIBITOR
The First Affiliated Hospital, Zhejiang University School of Medicine (Chine)
Inventeur(s)
Yao, Hangping
Huang, Fude
Li, Lanjuan
Wang, Wenan
Cao, Luxiang
Jiao, Changping
Wu, Nanping
Lu, Xiangyun
Abrégé
The use of phenylarsenic oxide and a derivative thereof in the prevention or treatment of coronavirus diseases, meanwhile also provided is the use of a PI4KIIIα specific inhibitor in the prevention or treatment of coronavirus diseases.
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide non condensés avec un autre cycle, p. ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase
3.
CHIMERIC GENETICALLY-ENGINEERED NANO VESICLE USED FOR REMOVING PATHOGENIC ANTIBODIES, PREPARATION METHOD THEREFOR, AND USE THEREOF
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Chen, Jianghua
Lin, Jinwen
Lv, Junhao
Abrégé
Provided are a chimeric genetically-engineered nano vesicle used for removing pathogenic antibodies, a preparation method therefor, and the use thereof, belonging to the technical field of biology. By means of lentivirus particle transfection, a stably transfected cell line of a protein A/G gene is constructed, so as to stably express protein A and protein G. A fusion protein A/G can overcome the defect of poor IgG3 binding capacity of pure protein A, thereby improving the effect of antibody IgG adsorption. In addition, using PLGA nanoparticles having relatively uniform particle sizes as the core of the target vesicle and mixing same with engineered cell membranes that are ruptured by compression can promote self-assembly of cell membranes, so as to form extracellular vesicle mimetics, thereby improving the stability of the target nano vesicle. The prepared and separated nano vesicle can be applied to in-vivo adsorption and removal of antibodies, has good biological safety, and avoids the risk of dialysis catheterization operation during using processes and the risks such as bleeding and allergy during treatment processes of immunoadsorption columns.
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (Chine)
Inventeur(s)
Wang, Xiawei
Zheng, Zhiguo
Abrégé
The invention relates to a preparation method of lifitegrast and intermediate compounds thereof. In particular, the invention relates to a synthesis method of lifitegrast, a key intermediate for synthesizing lifitegrast and solvates thereof, and a method for preparing lifitegrast by hydrolyzing the key intermediate or solvates thereof under alkaline condition.
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
5.
Method for Promoting Functional Cure of AIDS by Reducing HIV Reservoir with Lenalidomide
The First Affiliated Hospital Zhejiang University School of Medicine (Chine)
Inventeur(s)
Zhu, Biao
Liu, Xiang
Zhu, Xueling
Guo, Yongzheng
Peng, Xiaorong
Cao, Qing
Abrégé
The present invention provides a method for promoting functional cure of AIDS by reducing HIV reservoir with lenalidomide, the method including administering a therapeutically effective amount of lenalidomide to a patient. Also provided is a method for reducing intracellular P24 and cell-related HIV RNA in PBMCs derived from HIV patients in vitro with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks. Further provided is a method for inhibiting latent activator-induced activation of latent HIV cell line U1 with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
6.
Method for Improving or Treating Cognitive Dysfunction Complicating HIV-associated Cryptococcal Meningitis with Lenalidomide
The First Affiliated Hospital Zhejiang University School of Medicine (Chine)
Inventeur(s)
Zhu, Biao
Tao, Ran
Xiong, Ye
Peng, Xiaorong
Huang, Ying
Abrégé
The present invention provides a method for treating patients with cognitive dysfunction complicating HIV-associated CM with lenalidomide. Patients with HIV-associated CM develop IRIS, some of which develop cognitive dysfunction. The patients with HIV-associated CM-IRIS are diagnosed as having cognitive dysfunction by Chinese version of the Montreal Cognitive Assessment (MoCA) and International HIV Dementia Scale (IHDS). After the treatment with lenalidomide, the MoCA score and IHDS score of the patients are improved significantly, and the leukocyte, proteins, albumin, IgG and inflammatory cytokines (growth-related oncogene, interleukin [IL]-10, granulocyte-colony stimulating factor, IL-6, IL-8, complement factor H, tumor necrosis factor-α, and α2 macroglobulin) in cerebrospinal fluid are greatly reduced. The present invention widens the scope of application of lenalidomide, proposes a new treatment method for cognitive dysfunction caused by HIV-associated CM-IRIS, and provides a new idea for the research and development of new drugs for cognitive dysfunction caused by HIV-associated CM-IRIS.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
7.
HIF2α GENE MUTANT AND USE THEREOF IN CONSTRUCTION OF NAFLD MOUSE MODEL
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Cao, Hongcui
Yu, Jiong
Li, Lanjuan
Gao, Feiqiong
Abrégé
The present invention relates to an HIF2α gene mutant, a vector containing the mutant, and the use of the mutant in the construction of a non-alcoholic fatty liver disease (NAFLD) mouse model. The genetically mutated mouse constructed by means of using the mutant can be stably passaged, which can be used as a tool in the research of NAFLD, is used for researching the pathogenesis of the HIF2α gene in the NAFLD mice, and provides a research model having a genetic stability for research on the pathogenesis of NAFLD, a treatment method, drug screening, etc.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/89 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-injection
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
8.
UNIVERSAL IMMUNE EFFECTOR CELL, PREPARATION METHOD THEREFOR, AND USE THEREOF
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Zeng, Xun
Fang, Hongyu
Zhang, Yixi
Wang, Guocan
Abrégé
The present invention provides a universal immune effector cell, and in particular a universal CAR-T cell (IRU-CAR-T), a preparation method therefor, and use thereof. The universal CAR-T cell introduces a CAR and a mutated CnA or CnB fragment by using a gene editing technology. The combination use of the universal CAR-T cell of the present invention and an immunosuppressive drug to treat tumors can reduce the activity of T cells of a patient, thereby reducing the rejection reaction of the patient on the IRU-CAR-T cell, improving the colonization of the IRU-CAR-T cell in the patient and exerting the anti-cancer effect thereof. The universal immune effector cell of the present invention makes the strategy of withdrawal after use of the CAR-T possible, and can greatly improve the security of CAR-T therapy.
THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
ZHEJIANG UNIVERSITY (Chine)
Inventeur(s)
Zhang, Jing
Tian, Chen
Guo, Zhen
Abrégé
A method, system, composition, and kit for diagnosing and identifying a non-Alzheimer's disease (AD) cognitive disorder, i.e., a "non-AD cognitive disorder". The system for diagnosing a "non-AD cognitive disorder" comprises: a first examination module used for examining the central nervous system source biomarker of extracellular vesicles (EV) in the body fluid of a test subject, so as to confirm the number and the particle size of the EVs carrying the central nervous system source-specific marker; a second examination module used for examining the marker related to the non-AD cognitive disorder of the EV in the body fluid of the test subject so as to confirm the number and the particle size of the EVs carrying the marker related to the non-AD cognitive disorder; and a diagnosis and identification module for diagnosing whether the test subject suffers from a non-AD cognitive disorder, the diagnosis being based on the examination results of the central nervous system source marker and the marker related to the non-AD cognitive disorder respectively obtained by the first examination module and the second examination module.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
G01N 15/10 - Recherche de particules individuelles
10.
POLYPEPTIDE FOR PREPARING ONECUT3 ANTIBODY, AND RABBIT POLYCLONAL ANTIBODY AND APPLICATION THEREOF
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Tong, Hongyan
Luo, Yingwan
Zhu, Shuanghong
Lang, Wei
Abrégé
A polypeptide for preparing an ONECUT3 antibody, and a rabbit polyclonal antibody and an application thereof, relating to the technical field of biology. On one hand, a polypeptide for preparing an ONECUT3 antibody is provided; on the other hand, an anti-ONECUT3 antigen polypeptide rabbit polyclonal purified antibody and an application thereof are provided. The obtained anti-ONECUT3 antigen polypeptide rabbit polyclonal purified antibody has a specific recognition function for ONECUT3, almost has no contaminant band, reliably reflects the expression level of cell-level and tissue-level ONECUT3 proteins, has the capability of detecting endogenously and exogenously expressed ONECUT3 proteins, and has the detection capability superior to the effect achieved by commercial antibodies available on markets.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
11.
METHOD AND SYSTEM FOR DIAGNOSING CENTRAL NERVOUS SYSTEM DISEASE USING MULTIPLE BIOMARKERS IN PERIPHERAL BODY FLUID
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
XY EVERGREEN TECHNOLOGY COMPANY (Chine)
Inventeur(s)
Guo, Zhen
Song, Xueru
Han, Qingqing
Abrégé
The present invention provides a method and system for diagnosing a central nervous system disease, and a composition, and a kit. The diagnosing system comprises: a first detection module, used for detecting a central nervous system-derived marker in a biological body fluid of a subject; a second detection module, used for detecting a central nervous system disease-related marker in the biological body fluid of the subject; and a diagnosis module, diagnosing, on the basis of central nervous system-derived marker and central nervous system disease-related marker detection results respectively obtained by the first detection module and the second detection module, whether the subject suffers from a central nervous system disease.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
12.
UPPER LIMB REHABILITATION TRAINING SYSTEM INTEGRATING MULTI-SOURCE STIMULATION
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Chen, Zuobing
Qi, Binjie
Zhu, Xueqiong
Wang, Daming
Wu, Xiaohong
Abrégé
An upper limb rehabilitation training system integrating multi-source stimulation is provided and includes an upper limb rehabilitation body provided with first through fourth rigid rings, the first through fourth rigid rings are fixed with first rope knots, second rope knots, third rope knots and fourth rope knots respectively. The upper limb rehabilitation training system integrating multi-source stimulation simulates working principles of muscle more authentically by using linear drive method, and complies with laws of human kinematics. The linear drive method reduces many complex mechanical structures, and makes process of force transmission very easy. The upper limb rehabilitation training system integrating multi-source stimulation reduces weight of a rehabilitative robot, improves wearing comfort, and provides a basic guarantee for patients to devote themselves to rehabilitation training.
A61H 1/02 - Appareils d'exercice extenseurs ou de ployage
A61H 7/00 - Dispositifs de pétrissage par succionDispositifs non prévus ailleurs pour masser la peau par frottement ou brossage
A61F 7/00 - Appareils de chauffage ou de refroidissement pour traitement médical ou thérapeutique du corps humain
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
13.
METHOD FOR PREPARING LIFITEGRAST AND INTERMEDIATE COMPOUND OF LIFITEGRAST
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNTVERSITY SCHOOL OF MEDICINE (Chine)
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (Chine)
Inventeur(s)
Wang, Xiawei
Zheng, Zhiguo
Abrégé
A method for preparing lifitegrast and an intermediate compound of lifitegrast. Specifically, disclosed are a method for synthesizing lifitegrast, a key intermediate for synthesizing lifitegrast, a solvate of lifitegrast, and a method for preparing lifitegrast by hydrolyzing the solvate under an alkaline condition.
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
14.
HUMANIZED BROAD-SPECTRUM HIGH-NEUTRALIZING ANTI-SARS-COV-2 MONOCLONAL ANTIBODY AND APPLICATION
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Shao, Yiming
Zhu, Biao
Li, Dan
Wu, Nanping
Wang, Zheng
Hao, Yanling
Abrégé
Disclosed in the present invention are a group of humanized broad-spectrum anti-SARS-CoV-2 monoclonal neutralizing antibodies. The neutralizing antibodies of the present invention are screened by a single B cell flow sorting-antibody gene amplification and pairing expression technology, have a unique CDR region, can specifically bind to SARS-CoV-2, and can effectively neutralize current multiple international epidemic virus strains (new crown mutant A, British mutant B1.1.7, South Africa mutant B.1.351, Brazil mutant P.1, and Indian mutants B.1.617.1 and B1.617.2), wherein the IC 50 is about 0.1 μg/ml. The present invention also relates to a preparation method for and a use of the group of neutralizing antibodies. Every two of the three antibodies of the present invention have a synergistic virus neutralizing effect when used in combination. Therefore, the combination of the three antibodies can be used for COVID-19 emergency prevention and/or treatment, has the characteristics of full humanization, high expression and good stability, and is suitable for industrialization. In addition, the antibodies can also be used for preparing SARS-CoV-2 detection reagents, so as to discover effective neutralizing antigen epitopes and develop SARS-CoV-2 recombinant proteins and subunit vaccines.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/577 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet faisant intervenir des anticorps monoclonaux
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
A61P 31/14 - Antiviraux pour le traitement des virus ARN
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Ge, Wengang
Huang, He
Hu, Yongxian
Zhang, Mingming
Gao, Ming
Li, Xiuju
Zhang, Xingwang
Yu, Shuhui
Han, Lu
Ren, Jiangtao
He, Xiaohong
Wang, Yanbin
Abrégé
The present invention provides a method and a composition for cellular immunotherapy. Specifically, the present invention provides a method for treating diseases associated with CD7 expression, comprising administering to a subject a first dose of engineered immune cells containing a chimeric antigen receptor that specifically binds to CD7, the first dose being 0.1x106to 1x108 CAR+ cells/kg, wherein the subject receives a lymphodepletion therapy, prior to administration of the first dose, the lymphodepletion therapy comprising cyclophosphamide, fludarabine, etoposide, melphalan, or a combination thereof.
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Yao, Hangping
Huang, Fude
Li, Lanjuan
Wang, Wenan
Cao, Luxiang
Jiao, Changping
Wu, Nanping
Lu, Xiangyun
Abrégé
The present application relates to pharmaceutical field. Provided is the use of a PI4KIIIa specific inhibitor in the prevention or treatment of coronavirus diseases, wherein the PI4KIIIa specific inhibitor is phenylarsenic oxide, a derivative thereof, of formula (I), Gl, an analog thereof, Al, and an analog thereof, or Simeprevir and or an analog thereof; wherein the chemical structural formula of Al is: and wherein the chemical structural formula of Gl is: Also described is a method for screening a drug medicament for preventing or treating coronavirus diseases.
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
Inventeur(s)
Yao, Hangping
Huang, Fude
Li, Lanjuan
Wang, Wenan
Cao, Luxiang
Jiao, Changping
Wu, Nanping
Lu, Xiangyun
Abrégé
The use of phenylarsenic oxide and a derivative thereof in the prevention or treatment of coronavirus diseases, meanwhile also provided is the use of a PI4KIIIα specific inhibitor in the prevention or treatment of coronavirus diseases.
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
18.
APPLICATION OF NELFINAVIR IN PREPARATION OF DRUG FOR PREVENTING AND TREATING NOVEL CORONAVIRUS PNEUMONIA
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (Chine)
THE FIRST AFFILIATED HOSPITAL, ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE (Chine)
HAINAN HAIYAO CO., LTD. (Chine)
KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (Chine)
Inventeur(s)
Xu, Zhijian
Yao, Hangping
Xu, Yechun
Wu, Nanping
Peng, Cheng
Zheng, Min
Lu, Xiangyun
Su, Haixia
Cheng, Linfang
Liu, Fumin
Wu, Haibo
Jin, Changzhong
Wu, Zhigang
Shen, Jingshan
Zhu, Weiliang
Jiang, Hualiang
Li, Lanjuan
Zheng, Yongtang
Han, Jianbao
Song, Tianzhang
Feng, Xiaoli
Tian, Renrong
Li, Chuan
Yang, Junlin
Gong, Likun
Wu, Chunhui
Jiang, Xiangrui
Wang, Zhen
Abrégé
The present invention relates to an application of nelfinavir in the preparation of a drug for preventing and treating novel coronavirus pneumonia. Specifically, the present invention relates to a use of nelfinavir and a pharmaceutical composition thereof as 2019 novel coronavirus (2019-nCov) 3CL proteinase inhibitors in the preparation of a drug for treating and/or preventing and alleviating related diseases caused by a 2019 novel coronavirus infection, such as a respiratory tract infection and pneumonia.
brevets
